{"id":2734,"date":"2025-03-18T11:52:12","date_gmt":"2025-03-18T11:52:12","guid":{"rendered":"https:\/\/genosophy.gr\/product\/karkinos-tou-dermatos-2\/"},"modified":"2025-04-24T13:20:19","modified_gmt":"2025-04-24T13:20:19","slug":"karkinos-tou-dermatos-2","status":"publish","type":"product","link":"https:\/\/genosophy.gr\/en\/product\/karkinos-tou-dermatos-2\/","title":{"rendered":"Skin Cancer"},"content":{"rendered":"

Skin malignancies include basal cell carcinoma (BCC)<\/strong>, squamous cell carcinoma (SCC)<\/strong>, and melanoma<\/strong>. While most skin cancers are associated with UV exposure<\/strong>, approximately 10%<\/strong> have a hereditary genetic basis<\/strong>.<\/p>\n

The GENOSOPHY\u00ae Skin Cancer Genetic Panel<\/strong> analyzes 19 genes<\/strong>, offering advanced genetic insights for accurate risk assessment<\/strong> and personalized management<\/strong>.<\/p>\n

Conditions Covered by the Genetic Test<\/h3>\n
    \n
  • Hereditary Melanoma<\/strong><\/li>\n
  • Hereditary Basal Cell Carcinoma<\/strong><\/li>\n
  • BAP1 Tumor Predisposition Syndrome<\/strong> \u2013 melanoma, kidney cancer, mesothelioma<\/li>\n
  • Li-Fraumeni Syndrome (TP53)<\/strong> \u2013 melanoma and multiple other cancers<\/li>\n
  • Cowden Syndrome (PTEN)<\/strong> \u2013 melanoma, thyroid and breast cancer<\/li>\n
  • Xeroderma Pigmentosum<\/strong> \u2013 extreme sensitivity to UV and skin cancer risk<\/li>\n<\/ul>\n

    Clinical Benefits<\/h3>\n

    Diagnosis<\/h4>\n
      \n
    • Detection of pathogenic genetic variants<\/strong> associated with increased risk for melanoma and other skin cancers<\/li>\n
    • Differentiation<\/strong> between sporadic and inherited forms of skin cancer<\/li>\n<\/ul>\n

      Prognosis<\/h4>\n
        \n
      • Evaluation of personal and family risk<\/strong> for developing skin cancer<\/li>\n
      • Guidance for preventive monitoring<\/strong> and therapeutic interventions<\/strong><\/li>\n<\/ul>\n

        Management<\/h4>\n
          \n
        • Decision-making for enhanced surveillance<\/strong> or preventive interventions<\/strong><\/li>\n
        • Guidance on therapeutic strategy<\/strong>, such as immunotherapy or targeted therapy (e.g. BRAF\/MEK inhibitors) in patients with relevant mutations<\/li>\n<\/ul>\n

          Testing Procedure<\/h3>\n

          The process is simple and includes:<\/p>\n

            \n
          1. Collection of a blood or saliva sample<\/strong><\/li>\n
          2. Analysis of 19 genes<\/strong> associated with hereditary skin cancer and melanoma using Next Generation Sequencing (NGS)<\/strong><\/li>\n
          3. Results delivered in approximately 5 weeks<\/strong><\/li>\n<\/ol>\n

            Genetic counseling and interpretation of results is available from Professors at the Medical School of the National and Kapodistrian University of Athens (EKPA)<\/strong> as an optional service.<\/p>\n

            Genes Included in the Panel<\/h3>\n

            BAP1, BRCA1*, BRCA2, CDK4, CDKN2A, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, MITF, POT1, PTCH1, PTEN*, SUFU, TP53, WRN*, XPA, XPC<\/strong><\/p>\n

            Note:<\/strong> In addition to coding regions (exons), the GENOSOPHY\u00ae test analyzes numerous non-coding regions<\/strong>, such as promoters<\/strong> and introns<\/strong>, which may provide clinically relevant information. The sensitivity for detecting single nucleotide variants (SNVs)<\/strong>, indels<\/strong>, and copy number variants (CNVs)<\/strong> is >99%<\/strong>. Sensitivity may be slightly lower for genes marked with an asterisk (*).<\/p>\n","protected":false},"excerpt":{"rendered":"

            Skin malignancies include basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. While most skin cancers are associated with UV exposure, approximately 10% have a hereditary genetic basis. The GENOSOPHY\u00ae Skin Cancer Genetic Panel analyzes 19 genes, offering advanced genetic insights for accurate risk assessment and personalized management. Conditions Covered by the Genetic Test […]<\/p>\n","protected":false},"featured_media":2462,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[85],"product_tag":[],"class_list":{"0":"post-2734","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-oncologic-ipiresies-gia-epaggelmaties-en","8":"first","9":"instock","10":"taxable","11":"shipping-taxable","12":"product-type-simple"},"acf":[],"_links":{"self":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product\/2734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media\/2462"}],"wp:attachment":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media?parent=2734"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_brand?post=2734"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_cat?post=2734"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_tag?post=2734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}